Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise

Avisol Capital Partners
Investing Group Leader

Summary

  • Mirum Pharmaceuticals has two drugs, maralixibat and volixibat, targeting rare liver diseases involving cholestasis.
  • The company's lead program, maralixibat, was approved for Alagille syndrome and has a busy data drop schedule for label expansions.
  • Mirum's pipeline includes programs for PFIC, CTX, Biliary Atresia, and Adult Cholestasis, making it a proper liver disease franchise.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Anatomy of human body with liver. 3d illustration

Mohammed Haneefa Nizamudeen

I used to own Mirum Pharmaceuticals (MIRM) but let go after its first approval. I covered it last in May 2022. Mirum has two drugs, maralixibat (LIVMARLI) and volixibat, targeting a set of rare liver diseases involving cholestasis, or the

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-


Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 



This article was written by

Avisol Capital Partners
18.25K Followers

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About MIRM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on MIRM

Related Stocks

SymbolLast Price% Chg
MIRM
--
Compare

Trending Analysis

Trending News